Tenecteplase: Supply issue

Supply issue Active

There is a global supply issue affecting tenecteplase (a hospital-only medicine).

About this issue

The supplier of tenecteplase, Boehringer Ingleheim, has informed Pharmac that the supply issue is likely to remain until mid-2022.

We understand that limited supplies are available to cover demand through 2022.

Pharmac has not been able to source another brand of tenecteplase.

Alternative product

We have received clinical advice that alteplase is an appropriate alternative. There is enough stock of alteplase to manage any change in usage.

About alteplase in the NZ Formulary(external link)

Medsafe datasheet for alteplase [PDF](external link)

The Stroke Network and Ministry of Health have:

  • circulated advice on the use of tenecteplase and alteplase to DHBs (letter dated 28 Jan 2021)
  • provided an update on supply of tenecteplase (letter dated 18 Feb 2021).

Download the advice from the Stroke Network and Ministry of Health